Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.

Artificial intelligence (AI) Big data Digital human avatars (DHA) Genomics Lung cancer Machine learning Personalize medicine Precision medicine Radiomics System medicine

Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
13 Jun 2023
Historique:
received: 17 04 2023
accepted: 22 05 2023
medline: 15 6 2023
pubmed: 14 6 2023
entrez: 13 6 2023
Statut: epublish

Résumé

The current management of lung cancer patients has reached a high level of complexity. Indeed, besides the traditional clinical variables (e.g., age, sex, TNM stage), new omics data have recently been introduced in clinical practice, thereby making more complex the decision-making process. With the advent of Artificial intelligence (AI) techniques, various omics datasets may be used to create more accurate predictive models paving the way for a better care in lung cancer patients. The LANTERN study is a multi-center observational clinical trial involving a multidisciplinary consortium of five institutions from different European countries. The aim of this trial is to develop accurate several predictive models for lung cancer patients, through the creation of Digital Human Avatars (DHA), defined as digital representations of patients using various omics-based variables and integrating well-established clinical factors with genomic data, quantitative imaging data etc. A total of 600 lung cancer patients will be prospectively enrolled by the recruiting centers and multi-omics data will be collected. Data will then be modelled and parameterized in an experimental context of cutting-edge big data analysis. All data variables will be recorded according to a shared common ontology based on variable-specific domains in order to enhance their direct actionability. An exploratory analysis will then initiate the biomarker identification process. The second phase of the project will focus on creating multiple multivariate models trained though advanced machine learning (ML) and AI techniques for the specific areas of interest. Finally, the developed models will be validated in order to test their robustness, transferability and generalizability, leading to the development of the DHA. All the potential clinical and scientific stakeholders will be involved in the DHA development process. The main goals aim of LANTERN project are: i) To develop predictive models for lung cancer diagnosis and histological characterization; (ii) to set up personalized predictive models for individual-specific treatments; iii) to enable feedback data loops for preventive healthcare strategies and quality of life management. The LANTERN project will develop a predictive platform based on integration of multi-omics data. This will enhance the generation of important and valuable information assets, in order to identify new biomarkers that can be used for early detection, improved tumor diagnosis and personalization of treatment protocols. 5420 - 0002485/23 from Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore Ethics Committee. clinicaltrial.gov - NCT05802771.

Sections du résumé

BACKGROUND BACKGROUND
The current management of lung cancer patients has reached a high level of complexity. Indeed, besides the traditional clinical variables (e.g., age, sex, TNM stage), new omics data have recently been introduced in clinical practice, thereby making more complex the decision-making process. With the advent of Artificial intelligence (AI) techniques, various omics datasets may be used to create more accurate predictive models paving the way for a better care in lung cancer patients.
METHODS METHODS
The LANTERN study is a multi-center observational clinical trial involving a multidisciplinary consortium of five institutions from different European countries. The aim of this trial is to develop accurate several predictive models for lung cancer patients, through the creation of Digital Human Avatars (DHA), defined as digital representations of patients using various omics-based variables and integrating well-established clinical factors with genomic data, quantitative imaging data etc. A total of 600 lung cancer patients will be prospectively enrolled by the recruiting centers and multi-omics data will be collected. Data will then be modelled and parameterized in an experimental context of cutting-edge big data analysis. All data variables will be recorded according to a shared common ontology based on variable-specific domains in order to enhance their direct actionability. An exploratory analysis will then initiate the biomarker identification process. The second phase of the project will focus on creating multiple multivariate models trained though advanced machine learning (ML) and AI techniques for the specific areas of interest. Finally, the developed models will be validated in order to test their robustness, transferability and generalizability, leading to the development of the DHA. All the potential clinical and scientific stakeholders will be involved in the DHA development process. The main goals aim of LANTERN project are: i) To develop predictive models for lung cancer diagnosis and histological characterization; (ii) to set up personalized predictive models for individual-specific treatments; iii) to enable feedback data loops for preventive healthcare strategies and quality of life management.
DISCUSSION CONCLUSIONS
The LANTERN project will develop a predictive platform based on integration of multi-omics data. This will enhance the generation of important and valuable information assets, in order to identify new biomarkers that can be used for early detection, improved tumor diagnosis and personalization of treatment protocols.
ETHICS COMMITTEE APPROVAL NUMBER UNASSIGNED
5420 - 0002485/23 from Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore Ethics Committee.
TRIAL REGISTRATION BACKGROUND
clinicaltrial.gov - NCT05802771.

Identifiants

pubmed: 37312079
doi: 10.1186/s12885-023-10997-x
pii: 10.1186/s12885-023-10997-x
pmc: PMC10262371
doi:

Banques de données

ClinicalTrials.gov
['NCT05802771']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

540

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Anticancer Res. 2018 Apr;38(4):2155-2160
pubmed: 29599334
Int J Med Sci. 2013;10(3):320-30
pubmed: 23423768
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:771-4
pubmed: 26736376
Curr Pharm Des. 2014;20(38):5945-56
pubmed: 24641232
Sci Rep. 2018 Feb 19;8(1):3284
pubmed: 29459639
J Med Syst. 2020 Aug 4;44(9):161
pubmed: 32748066
Nat Biotechnol. 2018 Nov 9;36(11):1053-1055
pubmed: 30412185
Eur Urol. 2015 Jun;67(6):1142-1151
pubmed: 25572824
J Pers Med. 2022 Oct 20;12(10):
pubmed: 36294885
Int J Med Inform. 2017 Dec;108:1-8
pubmed: 29132615
Radiat Oncol. 2017 Sep 15;12(1):154
pubmed: 28915902
Sci Rep. 2016 Sep 20;6:33860
pubmed: 27645803
Genome Med. 2019 Dec 31;12(1):4
pubmed: 31892363
Nat Rev Clin Oncol. 2020 Dec;17(12):771-781
pubmed: 32843739
Acad Radiol. 2018 Dec;25(12):1548-1555
pubmed: 29572049
Oncotarget. 2017 Nov 01;8(61):104393-104407
pubmed: 29262648
Front Oncol. 2019 Oct 01;9:977
pubmed: 31632910

Auteurs

Filippo Lococo (F)

Catholic University of the Sacred Heart, Rome, Italy. filippo.lococo@policlinicogemelli.it.
Thoracic Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy. filippo.lococo@policlinicogemelli.it.

Luca Boldrini (L)

Catholic University of the Sacred Heart, Rome, Italy.
Radiotherapy Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Charles-Davies Diepriye (CD)

Radiotherapy Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Jessica Evangelista (J)

Catholic University of the Sacred Heart, Rome, Italy.
Thoracic Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Camilla Nero (C)

Catholic University of the Sacred Heart, Rome, Italy.
Division of Oncological Gynecology, Department of Woman and Child Health and Public Health, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Sara Flamini (S)

Thoracic Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Angelo Minucci (A)

Catholic University of the Sacred Heart, Rome, Italy.
Departmental Unit of Molecular and Genomic Diagnostics, Genomics Core Facility, Gemelli Science and Technology Park (G-STeP), A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Elisa De Paolis (E)

Departmental Unit of Molecular and Genomic Diagnostics, Genomics Core Facility, Gemelli Science and Technology Park (G-STeP), A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Clinical Chemistry, Biochemistry and Molecular Biology Operations (UOC), A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Emanuele Vita (E)

Catholic University of the Sacred Heart, Rome, Italy.
Medical Oncology, A. Gemelli University Hospital Foundation IRCCS, Largo A. Gemelli 8, Rome, Italy.

Alfredo Cesario (A)

Catholic University of the Sacred Heart, Rome, Italy.
Open Innovation, Scientific Directorate, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
CEO, Gemelli Digital Medicine & Health Srl, Rome, Italy.

Salvatore Annunziata (S)

Catholic University of the Sacred Heart, Rome, Italy.
Nuclear Medicine Unit, GsteP Radiopharmacy TracerGLab, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Maria Lucia Calcagni (ML)

Catholic University of the Sacred Heart, Rome, Italy.
Nuclear Medicine Unit, GsteP Radiopharmacy TracerGLab, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Marco Chiappetta (M)

Catholic University of the Sacred Heart, Rome, Italy.
Thoracic Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Alessandra Cancellieri (A)

Catholic University of the Sacred Heart, Rome, Italy.
Institute of Pathology, A. Gemelli University Hospital Foundation IRCCS, Roma, Italy.

Anna Rita Larici (AR)

Catholic University of the Sacred Heart, Rome, Italy.
Advanced Radiodiagnostic Center, Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Giuseppe Cicchetti (G)

Catholic University of the Sacred Heart, Rome, Italy.
Advanced Radiodiagnostic Center, Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Esther G C Troost (EGC)

Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Rossendorf, Germany.
OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, OncoRay - National Center for Radiation Research in Oncology, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz Association / Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.

Róza Ádány (R)

ELKH-DE Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Núria Farré (N)

Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (IR-HSCSP), Barcelona, Spain.

Ece Öztürk (E)

School of Medicine, Turkey and Koç University Research Center for Translational Medicine (KUTTAM), Sariyer, Koç University, Istanbul, Turkey.

Dominique Van Doorne (D)

Department of Philosophy and Educational Sciences, University of Turin - Academy of the Expert Patient ADPEE - EUPATI, Turin, Italy.

Fausto Leoncini (F)

Catholic University of the Sacred Heart, Rome, Italy.
Interventional Pulmonology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Andrea Urbani (A)

Catholic University of the Sacred Heart, Rome, Italy.
Clinical Chemistry, Biochemistry and Molecular Biology Operations (UOC), A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of Sacred Heart, Rome, Italy.

Rocco Trisolini (R)

Catholic University of the Sacred Heart, Rome, Italy.
Interventional Pulmonology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Emilio Bria (E)

Catholic University of the Sacred Heart, Rome, Italy.
Medical Oncology, A. Gemelli University Hospital Foundation IRCCS, Largo A. Gemelli 8, Rome, Italy.

Alessandro Giordano (A)

Catholic University of the Sacred Heart, Rome, Italy.
Nuclear Medicine Unit, GsteP Radiopharmacy TracerGLab, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Guido Rindi (G)

Catholic University of the Sacred Heart, Rome, Italy.
Institute of Pathology, A. Gemelli University Hospital Foundation IRCCS, Roma, Italy.

Evis Sala (E)

Catholic University of the Sacred Heart, Rome, Italy.
Advanced Radiodiagnostic Center, Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Giampaolo Tortora (G)

Catholic University of the Sacred Heart, Rome, Italy.
Medical Oncology, A. Gemelli University Hospital Foundation IRCCS, Largo A. Gemelli 8, Rome, Italy.

Vincenzo Valentini (V)

Catholic University of the Sacred Heart, Rome, Italy.
Radiotherapy Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Stefania Boccia (S)

Catholic University of the Sacred Heart, Rome, Italy.
Department of Life Sciences and Public Health, Catholic University of Sacred Heart, Rome, Italy.

Stefano Margaritora (S)

Catholic University of the Sacred Heart, Rome, Italy.
Thoracic Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Giovanni Scambia (G)

Catholic University of the Sacred Heart, Rome, Italy.
Division of Oncological Gynecology, Department of Woman and Child Health and Public Health, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH